LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...

(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...

Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking ...

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at ...

Pfizer Futures is Pfizer’s paid summer internship program for undergraduate students who want hands on experience at a global biopharmaceutical company. As a Pfizer Futures intern, you’ll work on real ...

The 230-acre site in Sanford, North Carolina, just south of the famed Research Triangle, is home to one of the largest U.S. biotechnology hubs. The site has flexible, multi-product manufacturing ...

In North Creek, our 4.8 acre facility manufactures various antibody drug conjugates (ADCs) and antibody intermediates. The site has a single-use ADC conjugation facility with processing up to 2kg ...

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide. Our strong pipeline—one of the most robust ...

Each September, government officials, global executives, NGOs and other key leaders converge on New York for the United Nations General Assembly. The week is marked by direct, cross-sector dialogues ...

This information is being provided pursuant to Colorado HB 19-1131. The information is accurate as of March 10 th, 2026. The prices listed are WAC prices, which represent Pfizer’s published list ...

Financial guidance for Adjusted (2) diluted EPS is calculated using approximately 5.74 billion weighted average shares outstanding, and assumes no share repurchases in 2024 or 2025.

Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 ...